Is NCT07717411 recruiting in Irvine, CA?

Yes, NCT07717411 is currently recruiting participants at its Irvine, CA location. This alzheimer's disease clinical trial is actively enrolling qualified participants.

How do I join the alzheimer's disease clinical trial in Irvine?

To join this clinical trial in Irvine, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Irvine clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Alzheimer's Disease Clinical Trial in Irvine, CA

About This Alzheimer's Disease Study in Irvine

This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild cognitive impairment (MCI) due to AD or dementia due to AD.

Sponsor: Hoffmann-La Roche

Who Can Participate

Inclusion Criteria

Body weight of 150 kg or less

Willingness and ability to complete all aspects of the study for the duration of the study

Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing (eyewear and hearing aids are permitted)

Cognitively and functionally unimpaired as defined by the protocol

Availability of a study partner as defined by the protocol

A plasma pTau217 level consistent with a high likelihood of future clinical progression

Exclusion Criteria

Any evidence of a condition other than AD that may affect cognition, including, but not limited to, frontotemporal dementia, dementia with Lewy bodies, vascular dementia, Parkinson disease, corticobasal syndrome, Creutzfeldt-Jakob disease, progressive supranuclear palsy, frontotemporal lobar degeneration (other than frontotemporal dementia), Huntington disease, normal pressure hydrocephalus, seizure disorder, delirium, or hypoxia

Mild cognitive impairment (MCI; may be referred to as prodromal AD), or any form of dementia

History or presence of clinically significant cerebrovascular disease

History of severe, clinically significant (persistent neurologic deficit or structural brain damage) central nervous system (CNS) trauma

History or presence of clinically significant intracranial mass

History of schizophrenia, schizoaffective disorder, major depression, or bipolar disorder

History or presence of any stroke with clinical symptoms within the past 12 months, or documented history within the last 12 months of an acute event that is consistent, in the opinion of the PI, with a transient ischemic attack

At risk for suicide in the opinion of the investigator

Substance abuse disorder within 12 months prior to screening (nicotine use is allowed)

Any other medical conditions (e.g., cardiovascular, hepatic, renal disease) which are not stable and adequately controlled or which in the opinion of the investigator could affect the participant's safety in the study or interfere with the study assessments

Uncontrolled hypertension

Impaired hepatic function

History or presence of any clinically significant hematological diseases

Diagnosis of a wet age-related macular degeneration (AMD)

Abnormal thyroid function

Abnormally low serum levels of folic acid or vitamin B12 deficiency that are judged to be clinically significant and/or may impact cognition as per the investigator's judgment

Current HIV, hepatitis B, or hepatitis C infection that has not been adequately treated in the opinion of the investigator

History of malignancy

Any previous administration of active immunotherapy (vaccine) that is being evaluated to prevent or postpone cognitive decline

Any previous or current use of passive immunotherapy (immunoglobulin) or other long-acting biologic agent that is approved or under evaluation or has been evaluated to prevent or postpone cognitive decline

Any other investigational treatment within 5 half-lives or 4 months prior to screening, whichever is longer

Intravenous (IV) or subcutaneous immunoglobulin therapy within 5 half-lives or 4 months prior to baseline whichever is longer

Anticoagulation medications at screening and there should be no plans to initiate any prior to or after randomization

Any treatment with cholinesterase inhibitors

Antipsychotic or neuroleptic medications within 3 months of screening, except as brief treatment for a non-psychiatric indication

Individuals with chronic use of opiates or opioids, benzodiazepines, barbiturates, or hypnotics, antidepressants or medication to treat anxiety should be on a stable dose for at least 8 weeks before baseline

Currently enrolled in an interventional study including those requiring investigational medicinal product (IMP) or involving any type of medical research that may interfere with study cognitive assessments

Residence in a skilled nursing facility such as a convalescent home or long-term care facility

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Irvine?

Yes, this clinical trial (NCT07717411) has an active research site in Irvine, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Alzheimer's Disease Treatment Options in Irvine, CA

If you're searching for alzheimer's disease treatment options in Irvine, CA, this clinical trial (NCT07717411) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Irvine research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced alzheimer's disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all alzheimer's disease clinical trials near you to find additional studies recruiting in your area.

Alzheimer's Disease Clinical Trial in Irvine, CA

Expert Care in Irvine

IRB Approved

No-Cost Care

Apply for This Irvine Location

Why Participate?

Simple Process